Related references
Note: Only part of the references are listed.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study
Bartolome R. Celli et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations
Gary T. Ferguson et al.
RESPIRATORY MEDICINE (2008)
Predictors of rehospitalization and death after a severe exacerbation of COPD
Ryan McGhan et al.
CHEST (2007)
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease
Peter Kardos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Risk indexes for exacerbations and hospitalizations due to COPD
Dennis E. Niewoehner et al.
CHEST (2007)
Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD
Denis E. O'Donnell et al.
CHEST (2006)
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
JJ Soler-Cataluña et al.
THORAX (2005)
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
EFM Wouters et al.
THORAX (2005)
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study
B Make et al.
CLINICAL THERAPEUTICS (2005)
Burden and clinical features of chronic obstructive pulmonary disease (COPD)
RA Pauwels et al.
LANCET (2004)
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
BR Celli et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the diskus inhaler for the treatment of COPD
NA Hanania et al.
CHEST (2003)
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
P Calverley et al.
LANCET (2003)
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease - The COPE study
P van der Valk et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in them treatment of chronic obstructive pulmonary disease
DA Mahler et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
GC Donaldson et al.
THORAX (2002)
Share Paper
